Status:
COMPLETED
Aspirin Responsiveness and Outcome in Coronary Artery Bypass Graft (CABG) Surgery
Lead Sponsor:
University Hospital, Basel, Switzerland
Conditions:
Coronary Artery Bypass Graft Triple Vessel
Myocardial Ischemia
Eligibility:
All Genders
18+ years
Brief Summary
In patients undergoing coronary artery bypass graft (CAGB) surgery, aspirin is commonly prescribed to prevent graft thrombosis and myocardial ischemia. However, there are still a significant number of...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- patient undergoing elective CABG surgery
- therapy with aspirin until at least 2 days before surgery
- written informed consent
- Exclusion criteria:
- missing written consent
- no therapy with aspirin or therapy stopped more than 2 days before surgery
- therapy with clopidogrel more than 3 days before surgery
- emergency surgery
- surgery including more than CABG
- inborn or acquired platelet disorders
- therapy with Selective Serotonin reuptake inhibitors (SSRI)
- severe hepatopathy (spontaneous Quick \<70%)
- severe kidney disease (creatinine clearance \< 30 ml/min)
Exclusion
Key Trial Info
Start Date :
June 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 1 2013
Estimated Enrollment :
304 Patients enrolled
Trial Details
Trial ID
NCT01174862
Start Date
June 1 2010
End Date
June 1 2013
Last Update
March 10 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Anaesthesia and Intensive Care Unit, Univeristy Hospital Basel, Switzerland
Basel, Canton of Basel-City, Switzerland, 4031